/
ALLR
$1.30+$0.00 (+0.00%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$20.7M
16M shares
52-week range
$0.77 – $2.35
34% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
3.27%
Moderate
Price (6 mo)
Loading chart…
Change$-8819998.70
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $120.0K | $0 | $0 | $0 | $0 | $0 | $320.0K |
| Cost of revenue | $5.1M | $0 | $0 | $106.0K | $120.0K | $0 | $0 | $0 |
| Gross profit | −$3.6M | $120.0K | $0 | −$106.0K | −$120.0K | $0 | $0 | $320.0K |
| Gross margin | -247.9% | 100.0% | — | — | — | — | — | 100.0% |
| R&D | $0 | $6.4M | $4.2M | $14.2M | $6.9M | $7.1M | $6.1M | $6.6M |
| Operating income | −$5.0M | −$17.6M | −$8.3M | −$26.6M | −$34.5M | −$17.1M | −$27.2M | −$12.6M |
| EBITDA | −$4.9M | −$15.6M | −$6.0M | −$25.8M | −$17.3M | −$11.3M | −$24.2M | −$11.0M |
| Net income | −$2.3M | −$14.3M | −$6.6M | −$26.6M | −$16.1M | −$11.9M | −$24.5M | −$11.2M |
| Net margin | -157.0% | -11927.5% | — | — | — | — | — | -3509.7% |
| EPS (diluted) | 0.00 | -189613.00 | -1698639.00 | -79074.18 | -31799.09 | -6031.31 | -15.79 | -0.78 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $100M | $-0.92 | $-0.92–$-0.92 | 1 |
| 2027 | $86M | $-0.97 | $-0.97–$-0.97 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.25
Price
$1.30
Implied downside
-4%
Peer comparison
Allarity Therapeutics, Inc. Common Stock
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
www.allarity.com- Employees
- 8
- IPO / List date
- Dec 21, 2021
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds ALLR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 228,084 | $248.6K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-09-11 | 1-for-30reverse |
| 2024-04-09 | 1-for-20reverse |
| 2023-06-29 | 1-for-40reverse |
| 2023-03-27 | 1-for-35reverse |
Recent trades on TradeandTell
No one on the platform has traded ALLR yet.
